Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.80 |
| ▸ | MAPT | P10636 | 4/20 | 0.80 |
| ▸ | TSHR | P16473 | 2/20 | 0.80 |
| ▸ | NPC1 | O15118 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | STAT3 | P40763 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.61 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL663265 | 0.86 | KMT2A (0.74) | KMT2AMEN1SMN1; SMN2LMNAMAPT | |
| SCHEMBL10187017 | 0.85 | NR3C1 (0.81) | KMT2AMEN1SMN1; SMN2LMNAMAPT | |
| SCHEMBL663647 | 0.84 | KMT2A (0.72) | KMT2AMEN1SMN1; SMN2LMNAMAPT | |
| SCHEMBL12197865 | 0.83 | KMT2A (0.71) | KMT2AMEN1SMN1; SMN2LMNAMAPT | |
| SCHEMBL30926609 | 0.83 | KMT2A (0.70) | KMT2AMEN1SMN1; SMN2LMNAMAPT | |
| SCHEMBL27180717 | 0.83 | KMT2A (0.70) | KMT2AMEN1SMN1; SMN2LMNAMAPT | |
| SCHEMBL665117 | 0.83 | MAPT (0.75) | KMT2AMEN1SMN1; SMN2LMNAMAPT | |
| SCHEMBL15836647 | 0.82 | KMT2A (0.70) | KMT2AMEN1SMN1; SMN2LMNAMAPT | |
| SCHEMBL20657280 | 0.82 | KMT2A (0.69) | KMT2AMEN1SMN1; SMN2LMNAMAPT | |
| SCHEMBL20657281 | 0.82 | KMT2A (0.69) | KMT2AMEN1SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021509-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A1, SLC20A1 | KMT2A 4634/4885MEN1 2248/4885SMN1; SMN2 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.